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All treatment plans were met the clinically acceptable goals. 
The 4D-IMRT showed a statistically significant improvement 
(p<0.05) compared to 3D-IMRT in all relevant parameters. 
The 4D-VMAT plans further reduced all OAR parameters 
significantly (p<0.05), while maintaining identical target 
coverage. Phantom measurements confirmed that both 
techniques (IMRT and VMAT) can be safely administered.  
 
Conclusion: By using the 4D-CT acquisition and mid-
ventilation target delineation approach, significant PTV 
volume reduction was obtained. This method is improving 
PTV coverage and OAR doses using the same technique 
(IMRT). VMAT technique might further gain additional 
dosimetric benefits for patients with NSCLC.  
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Purpose or Objective: We applied a variety of published 
conventional and stereotactic plan quality dosimetric indices 
to describe and discern clinically achieved target dose 
distributions in Lung SBRT. 
 
Material and Methods: Treatment plans of 100 Lung SBRT 
patients treated were retrospectively reviewed. The targets 
(n=102) were evenly distributed – right lung (53) and left lung 
(49). Patients were prescribed to a total dose of 50-60 Gy in 
3-5 fractions. Dose optimizations were accomplished with 6 
MV using either 2-5 arcs VMAT (90); 8-14 IMRT fields (6) or 10-
16 static fields (6). Dose calculations were performed using 
AAA algorithm with heterogeneity correction. A literature 
review on dosimetric indices recommended for qualitative 
analyses of conventional and stereotactic dose distributions 
in target coverage, homogeneity, conformity and gradient 
categories was performed. From each patient treatment 
plan, the necessary parameters for calculating various indices 
were quantified. 
 
Results: For the study, the mean (±SD) values for indices 
were: coverage (96.4 (±2.4) %); homogeneity (1.27 (±0.07)); 
Conformity (1.04 (±0.08)) and Gradient 1.27(±0.30) cm). 
Geometric conformity (g) strongly correlated with the 
conformity index (defined by van’t Riet /Paddick)(p<0.0001). 
All Gradient measures strongly correlated with PTV 
(p<0.0001). Evaluating High Dose Spillage, the average 
cumulative volume of all tissue outside the PTV receiving a 
dose of > 105% of prescription dose was 0.94 (± 1.64) %. 
Considering Low Dose Spillage, the maximum % of 
prescription dose to any point at 2 cm distance in any 
direction from PTV was 56.0 (± 11.4) %. The lung volume 
(total lung volume – GTV) receiving doses of 20 Gy and 5 Gy 
(V20 and V5) were mean 4.9 % (± 3.1) and 16.9 % (± 9.0). The 
RTOG lung SBRT protocol advocated conformity guidelines for 
prescribed dose in all dosimetric evaluation categories were 
met in ≥94% of cases.  
 
Conclusion: The high-rate of adherence to RTOG protocol 
dose conformancy guidelines in our study validates that 
indices derived from our SBRT lung plan dose distributions 
are a tool for establishing plan metrics in clinical trials, for 
scoring competing plans and as well as for comparing inter-
institutional lung SBRT plan dosimetric data. However, these 
indices should only be used as an additional tool to grade 
plan quality once a satisfactory treatment plan has been 
achieved judged on the basis of clinical expertise, acceptable 
dose distributions and dose gradients, while respecting 
critical organ and normal structure doses. 
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Purpose or Objective: Improvements in overall survival of 
pancreatic cancer patients after carbon ion radiotherapy 
have been reported from Japanese clinical trials. Due to the 
sharp distal dose fall-off, a high dose can be delivered to the 
tumor, while sparing the nearby healthy organs. However, 
changes in gastrointestinal gas volumes can greatly influence 
the carbon ion range. 
We evaluated the robustness of carbon ion therapy for 
pancreatic cancer patients by investigating the impact of 
interfractional anatomical changes on the accumulated dose 
when using bony anatomy- and fiducial marker-based position 
verification. 
 
Material and Methods: Nine pancreatic cancer patients, 
treated with photon radiotherapy in free breathing, were 
included in this retrospective planning study. The internal 
gross tumor volume (iGTV), internal clinical target volume 
(iCTV), duodenum, stomach, liver, spinal cord and kidneys 
were delineated on the (average) 4D-CT scan. Intratumoral 
gold fiducial markers were implanted in all patients to enable 
position verification using cone beam CT (CBCT). 
Treatment plans were created using a 4-beam passive 
scattering technique. A smearing technique was used to 
account for patient setup errors; a safety margin of 3 mm 
was applied to compensate for range uncertainties. Plans 
were generated to deliver at least 95% of the prescribed dose 
(36GyE in 12 fractions) to 99% of the iCTV. 
To enable dose calculations on the daily CBCTs, the planning 
CT was deformably registered to each CBCT. The 
gastrointestinal gas volume visible on each CBCT was copied 
to the deformed CTs. Next, fraction doses were calculated by 
aligning the treatment plan according to a bony anatomy- 
and a fiducial marker-based registration. For both 
registration methods the resulting fraction doses were rigidly 
summed to acquire the accumulated dose. 
We compared both accumulated doses to the planned dose 
using dose-volume histograms (DVHs) and calculated DVH 
parameters for the iGTV and iCTV (Dmean, D2%, D98%) and 
organs at risk (Dmean, D2cc). 
 
Results: The D98% of the target volumes showed the largest 
differences (Figure). For the bony anatomy-based 
registration, D98% reduced significantly from 99.6% ± 0.2% 
(iGTV; mean ± standard deviation) and 98.6% ± 0.5% (iCTV) as 
planned to 92.3% ± 3.8% and 81.9% ± 7.7% for the 
accumulated dose, respectively. For the marker-based 
registration, this was slightly improved to 95.1% ± 4.0% (iGTV) 
and 88.6% ± 4.0% (iCTV), which was still significantly 
different from planned. 
For the duodenum, severe deviations were observed in the 
DVHs between the planned and accumulated dose. Both the 
direction and magnitude of the deviations differed 
considerably between patients. The other organs showed 
minor changes. 
